ArticleBMC research notes2025
Upregulation of PCAT1, PCAT2, and PCAT3 LncRNAs in cervical cancer patients and their diagnostic value.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of long non-coding RNAs in therapy resistance of cervical cancer and therapeutic potential.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCervical cancer is one of the most common cancers among women. Despite advances in vaccination and screening, barriers to early detection and effective treatment remain. lncRNAs play an important role in cancer progression and therapeutic responses. New lncRNAs such as PCAT1, PCAT2, and PCAT3 have shown oncogenic activities in multiple cancers, but their role in cervical cancer is not understood. This study investigated the expression patterns of PCAT1, PCAT2, and PCAT3 in cervical cancer to evaluate their use as diagnostic markers and therapeutic targets.
resultsThe expression level of PCAT1, PCAT2, and PCAT3 was significantly (P value < 0.05) higher in tumor tissues.ROC analysis showed a moderate diagnostic biomarker value for PCAT1 (AUC 0.79, sensitivity 79%, specificity 69%). Spearman's analysis showed a positive correlation between PCAT1-PCAT2 and PCAT1-PCAT3. PCAT1, PCAT2, and PCAT3 lncRNAs significantly increase in cervical cancerous tissues and may play a role as novel oncogenes. Their use as clinical diagnostic markers requires further studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.